Signature Medical is developing AcoustiCare, its flagship wearable product focused on heart failure evaluation and monitoring to improve patient outcomes while preventing hospital re-admissions.
It differs from other typical sensor-based wearables with its proprietary cloud-based audio technology and artificial intelligence enabling remote monitoring and evaluation of heart failure and other indications.
Proceeds from this financing will be used to accelerate the development and commercialization of the AcoustiCare system.
Signature Medical offers innovative solutions focused on value-based healthcare initially focused on heart failure. It is dedicated to improving outcomes while reducing costs in high-value, large underserved markets using proprietary cloud-based and wearable technology.
Riot is an early-stage venture fund that invests in emerging technologies such as artificial intelligence, internet of things, autonomous vehicles, robotics, and augmented and virtual reality. Riot is headquartered in Boston with offices in Los Angeles.
Bose Corp. invests in long-term research with one fundamental goal: to develop new technologies with real customer benefits. Bose innovations have spanned decades and industries, creating and transforming categories in audio and beyond.
Phrontline Biopharma doses first patient in TJ101 Phase 1 clinical trial
Gene Solutions' mitochondrial therapy platform targeting neurological diseases secures patent
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Avidity Biosciences prices upsized common stock public offering
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Endo to share PFI and PFA data at American Orthopaedic Foot & Ankle Society Annual Meeting
Diamyd Medical secures Eurasian patent for insulin-based antigen therapy in type 1 diabetes
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
AMO Pharma signs licence agreement with PHRI and Venca Research Inc to advance new study in ARVC
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD